"This study provides us with a starting point for understanding how tumors physiologically respond to therapy and a non-invasive technique for monitoring that response," Dr. Diaz said.
Cellular pharmacogenomic to discover genetic determinants of Tykerb response: Abstract 5684
A new high-throughput genetic analysis technique can reveal gene markers ?by the dozens ?that determine how a patient might respond to certain cancer drugs, according to scientists at the Translational Genomics Research Institute (TGen). The TGen researchers have found 164 genes that are involved in regulating the sensitivity of squamous cell head and neck cancer cells to lapatinib, a cancer drug that was recently approved for use in metastatic breast cancer under the name Tykerb.
The study, a collaboration with GlaxoSmithKline, evaluated 7,000 genetic targets in human head and neck cancer cells to discover specific genes that might shade an individual’s response to Tykerb.
"Our goal is to apply advanced cellular genomic strategies to assist clinical drug development by finding gene states that predict a patient’s response to a specific drug, and which combination of drugs produce the most favorable response." said Spyro Mousses, Ph.D., director of the Pharmaceutical Genomics Division at TGen. "In this study, we were able to discover new candidate gene states that may be useful in determining a patient’s sensitivity or resistance to Tykerb, and the results have revealed several sensitizing drug targets that reveal a set of candidate combination drugs that are predicted to be synergistic with Tykerb."
Tykerb is an enzyme inhibitor that effectively blocks two cell receptors
Source:American Association for Cancer Research